Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. - 23. (Cancelled)

24. (Withdrawn) An electronic device comprising:

a bezel, wherein an outer surface of at least a portion of the bezel comprises a first visual characteristic; and

a heart sensor coupled to the at least a portion of the bezel and operative to detect a user's cardiac signal, wherein an outer surface of the heart sensor comprises a second visual characteristic that matches the first visual characteristic.

25. (Withdrawn) The electronic device of claim 24, wherein each of the outer surface of the at least a portion of the bezel and the outer surface of the heart sensor comprises a portion of an outer surface of the electronic device.

26. (Withdrawn) The electronic device of claim 24, wherein:

the outer surface of the at least a portion of the bezel comprises a first finish; and

the outer surface of the heart sensor comprises a second finish that matches the first finish.

27. (Withdrawn) The electronic device of claim 24, wherein the outer surface of the heart sensor comprises a conductive coating that provides the second visual characteristic.

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
76 of 363

28. (Withdrawn) The electronic device of claim 24, wherein each of the first visual characteristic and the second visual characteristic comprises at least one of:

a particular color;

a particular tone; and

a particular reflectivity.

29. (Currently Amended) An electronic device for detecting a user's cardiac signal, comprising:

an enclosure;

a heart sensor configured to detect the user's cardiac signal, the heart sensor comprising:

a first lead comprising a first pad that is embedded in a first portion of the enclosure, wherein an exterior surface of the enclosure comprises an exterior surface of the first portion, wherein the first ~~lead~~ pad is positioned underneath the exterior surface of the first portion, and wherein the first ~~lead~~ pad is configured to detect a first electrical signal of the user's cardiac signal via the user's skin's contact with the exterior surface of the first portion of the enclosure; and

a second lead comprising a second pad that is embedded in a second portion of the enclosure, wherein the second ~~lead~~ pad is configured to detect a second electrical signal of the user's cardiac signal via the user's skin's contact with at least one of the second ~~lead~~ pad and the second portion of the enclosure; and

a processor coupled to the heart sensor and configured to receive and process the detected cardiac signal, wherein the first lead further comprises a first connector coupled to the first pad and configured to provide the first electrical signal detected by the first pad to the processor, and wherein the second lead further comprises a second connector coupled to the second pad and configured

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
77 of 363

to provide the second electrical signal detected by the second pad to the processor.

30. (Previously Presented) The electronic device of claim 29, wherein the first portion and the second portion are located on opposite sides of the electronic device.

31. (Previously Presented) The electronic device of claim 29, wherein the first portion is electrically isolated from the second portion.

32. (Currently Amended) The electronic device of claim 29, wherein:

the first portion is separated from the second portion by a third portion of the enclosure;

at least the third portion is constructed from a material having a first conductivity; and

the first conductivity is insufficient to transmit the first electrical signal from the first ~~lead~~ pad to the second ~~lead~~ pad via the third portion.

33. (Currently Amended) The electronic device of claim 32, wherein:

the material having the first conductivity comprises one of aluminum and steel; and

the second ~~lead~~ pad is constructed from a silver based compound.

34. (Currently Amended) The electronic device of claim 32, wherein:

the exterior surface of the enclosure further

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
78 of 363

comprises an exterior surface of the second portion;

the second ~~lead~~ pad is configured to detect the second electrical signal of the user's cardiac signal via the user's contact with the exterior surface of the second portion;

the second ~~lead~~ pad is positioned from the exterior surface of the second portion by a thickness of the second portion;

at least the thickness of the second portion is constructed from material having a second conductivity; and

the second conductivity is defined such that the second electrical signal is not able to be transmitted through material having the second conductivity over a distance larger than the thickness of the second portion.

35. (Currently Amended) The electronic device of claim 34, wherein the first ~~lead~~ pad and the second ~~lead~~ pad are positioned apart from one another at a distance larger than the thickness of the second portion by material having the second conductivity.

36. (Currently Amended) The electronic device of claim 29, wherein:

the enclosure further comprises at least one pocket underneath the exterior surface of the enclosure; and

at least one of the first ~~lead~~ pad and the second ~~lead~~ pad is placed within the at least one pocket.

37. (Cancelled)

38. (Cancelled)

39. (Previously Presented) The electronic device of claim 29, further comprising:

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
79 of 363

a display, wherein the enclosure supports the display, and wherein at least a portion of the exterior surface of the enclosure forms at least a portion of an exterior surface of the electronic device behind the display; and

a third lead embedded with the display, wherein the third lead is configured to detect a third electrical signal of the user's cardiac signal via the user's contact with at least one of the third lead and the display.

40. (Currently Amended) An electronic device for detecting a user's cardiac signal, comprising:

an enclosure;

a display screen exposed to the user through an opening in the enclosure;

a heart sensor configured to detect the user's cardiac signal, the heart sensor comprising:

a first lead embedded in a first portion of the enclosure of the electronic device, wherein the first lead is configured to detect a first electrical signal of the user's cardiac signal via the user's contact with at least one of the first lead and the first portion of the enclosure of the electronic device; and

a second lead embedded in ~~a second portion~~ the display screen of the electronic device, wherein the second lead is configured to detect a second electrical signal of the user's cardiac signal via the user's contact with at least one of the second lead and the ~~second portion~~ display screen of the electronic device; and

a processor coupled to the heart sensor and configured to process the first and second electrical signals of the user's cardiac signal~~, wherein:~~

~~the first portion of the electronic device comprises an enclosure of the electronic device; and~~

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
80 of 363

~~the second portion of the electronic device comprises a display screen exposed to the user through an opening in the enclosure of the electronic device~~.

41. (Cancelled)

42. (Currently Amended) The electronic device of claim 40, wherein:

the first portion of the electronic device comprises a bezel of the enclosure;

the electronic device further comprises a non-conductive component positioned between the bezel and the display screen for electrically isolating the first ~~portion of the electronic device~~ lead from the second ~~portion of the electronic device~~ lead.

43. (Cancelled)

44. (New) The electronic device of claim 29, wherein the second lead is configured to detect the second electrical signal of the user's cardiac signal via the user's contact with the second portion of the enclosure.

45. (New) The electronic device of claim 29, wherein the second lead is configured to detect the second electrical signal of the user's cardiac signal via the user's contact with the second lead.

46. (New) The electronic device of claim 40, wherein the first lead is configured to detect the first electrical signal of the user's cardiac signal via the user's contact with the first lead.

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
81 of 363

47. (New) The electronic device of claim 46, wherein the second lead is configured to detect the second electrical signal of the user's cardiac signal via the user's contact with the second lead.

48. (New) The electronic device of claim 46, wherein the second lead is configured to detect the second electrical signal of the user's cardiac signal via the user's contact with the display screen.

49. (New) The electronic device of claim 40, wherein the first lead is configured to detect the first electrical signal of the user's cardiac signal via the user's contact with the first portion of the enclosure.

50. (New) The electronic device of claim 49, wherein the second lead is configured to detect the second electrical signal of the user's cardiac signal via the user's contact with the second lead.

51. (New) The electronic device of claim 49, wherein the second lead is configured to detect the second electrical signal of the user's cardiac signal via the user's contact with the display screen.

52. (New) The electronic device of claim 29, wherein the first portion of the enclosure is a bezel.

53. (New) The electronic device of claim 29, wherein the second portion of the enclosure is a bezel.

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
82 of 363

54. (New) The electronic device of claim 29, wherein an interior surface of the enclosure comprises an interior surface of the first portion, wherein the first pad is positioned on the interior surface of the first portion.

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
83 of 363

REMARKS

Introduction

Claims 1-23, 37, 38, 41, and 43 have been cancelled without prejudice. Applicants hereby reserve the right to pursue the subject matter of one or more of cancelled claims in one or more continuation applications. Claims 24-28 have been withdrawn without prejudice. Claims 44-54 have been added. Claims 29, 32-36, 40, and 42 have been amended. Claims 30, 31, and 39 are also currently pending in the above-identified patent application. No new subject matter has been introduced and all amendments are fully supported by the application as originally filed.

Claims 29-32 and 36 have been rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Gilles et al. U.S. Patent No. 4,635,646 (hereinafter "Gilles").

Claims 33-35, 39, 40, and 42 have been rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Gilles.

A three-month extension of time in which to respond to the Final Office Action mailed March 2, 2016 is respectfully requested. It is noted that a one-month extension was previously requested and paid for with the Reply filed June 30, 2016. The required fees are being paid by credit card, but the Director is authorized to charge any underpayment or to credit any overpayment to Deposit Account No. 50-6007.

Reconsideration and allowance of this application in light of the following remarks is hereby respectfully requested.

Summary of Examiner Interview

Applicants would like to thank the Examiner for the many courtesies extended during the interview of August 18, 2016 with the undersigned and the interview of August 23, 2016 with the undersigned (herein after "the Examiner Interviews"). During the interviews, the

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
84 of 363

currently amended claims were discussed in light of the cited references.

The Rejections Under 35 U.S.C. § 102(b)

Claims 29-32 and 36 have been rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Gilles. These rejections are respectfully traversed.

Applicants' amended independent claim 29 defines an electronic device for detecting a user's cardiac signal, including an enclosure, a heart sensor configured to detect the user's cardiac signal, and a processor coupled to the heart sensor. The heart sensor includes a first lead including a first pad that is embedded in a first portion of the enclosure, wherein an exterior surface of the enclosure includes an exterior surface of the first portion, wherein the first pad is positioned underneath the exterior surface of the first portion, and wherein the first pad is configured to detect a first electrical signal of the user's cardiac signal via the user's skin's contact with the exterior surface of the first portion of the enclosure. The heart sensor also includes a second lead including a second pad that is embedded in a second portion of the enclosure, wherein the second pad is configured to detect a second electrical signal of the user's cardiac signal via the user's skin's contact with at least one of the second pad and the second portion of the enclosure. The processor is configured to receive and process the detected cardiac signal, wherein the first lead further includes a first connector coupled to the first pad and configured to provide the first electrical signal detected by the first pad to the processor, and wherein the second lead further includes a second connector coupled to the second pad and configured to provide the second electrical signal detected by the second pad to the processor.

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
85 of 363

For example, "[h]eart sensor 112 can include one or more leads connected to the exterior of the electronic device such that the user may contact one or more of the leads to provide an electrical signal associated with the user's heart to heart sensor 112," and "[t]he cardiac signals detected by the heart sensor leads can be coupled to a processor incorporated in heart sensor 112, or instead provided to processor 102," where "[t]he processor may then analyze the received signals and generate, from the received signals, one or more characteristic quantities of the user's heartbeat or heart rate for authentication" (applicants' specification, paragraph [0033]). The "size and location of the leads can be selected to ensure that sufficient contact is made between the user (e.g., the user's hand or finger) and the leads for cardiac signals to be detected," where "each lead can include a pad or extended area placed on the outer or inner surface of an electronic device bezel or housing" or "an entire portion of the electronic device enclosure (e.g., a portion of a bezel or housing) can serve as a lead for the heart sensor," and the "pad or extended area can then be coupled to a wire or other connector for providing cardiac signals to a processor for processing" (applicants' specification, paragraph [0034]), such as leads 322 and 324 of FIG. 3. As a specific example, with respect to applicants' FIG. 4B, an enclosure of electronic device 450 may include a bezel 460, where, "[i]f the electrical conductivity and size of bezel 460, and the strength or characteristics of the cardiac signal provided by the user and detected by the heart sensor are adapted such that the signal can be transmitted along short distances in bezel 460, lead 472 of the heart sensor can be positioned against the back surface of bezel 460," or "lead 472 can be placed within the thickness of bezel 460 (e.g., in a pocket within the bezel wall), but underneath the outer surface of the bezel," where a "short thickness

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
86 of 363

of bezel 460 can allow electrical signals to propagate from the user to the outer surface of bezel 460, through bezel 460, and into lead 472, which may in turn transmit the signals to a processor using connector 474" (applicants' specification, paragraph [0047]).

Gilles is directed towards heart monitoring apparatus. Gilles' FIG. 5 shows apparatus including an auxiliary device 9 with a male coupling 11 on one face for coupling to a case 3, and a female coupling 12 on another face for coupling to auxiliary electrode 7. Auxiliary device 9 is connected to several other auxiliary electrodes 13, 14, and 15 which adhere to the patient's bust in pre-determined positions via wires, as shown in Gilles' FIG. 8.

Nowhere does Gilles show or suggest an electronic device with an enclosure and a heart sensor with a first pad embedded in a first portion of the enclosure and a second pad embedded in a second portion of the enclosure, where "an exterior surface of the enclosure comprises an exterior surface of the first portion, wherein the first pad is positioned underneath the exterior surface of the first portion, and wherein the first pad is configured to detect a first electrical signal of the user's cardiac signal via the user's skin's contact with the exterior surface of the first portion of the enclosure," as required by applicants' amended independent claim 29. That is, nowhere does Gilles show or suggest any electrode embedded in any portion of case 3 / auxiliary device 9, let alone show or suggest a first electrode embedded in a first portion of case 3 / auxiliary device 9 and a second electrode embedded in a second portion of case 3 / auxiliary device 9. Instead, each one of auxiliary electrodes 13, 14, and 15 of Gilles is distinct and independent from case 3 / auxiliary device 9 and is remotely coupled to case 3 / auxiliary device 9 via one or more wires of Gilles' FIG. 8.

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
87 of 363

On pages 2 and 3 of the Office Action, the Examiner attempts to equate the wire connecting electrode 13 to case 3 / auxiliary device 9 with the first lead of applicants' independent claim 29 and to equate the wire connecting electrode 14 to case 3 / auxiliary device 9 with the second lead of applicants' independent claim 29. However, applicants' amended independent claim 29 requires its first lead to include a first pad configured to "detect a first electrical signal of [a] user's cardiac signal via the user's skin's contact with [an] exterior surface of [a] first portion of [an] enclosure [in which the first pad is embedded]," and nowhere does Gilles show or suggest that the wire connecting electrode 13 to case 3 / auxiliary device 9 is configured to detect an electrical signal of a user's cardiac signal via the user's skin's contact with an exterior surface of case 3 / auxiliary device 9. Instead, Gilles' electrode 13 is only configured to detect an electrical signal of a user's cardiac signal via the user's contact with electrode 13, which is clearly distinct from and not embedded in case 3 / auxiliary device 9.

For at least these reasons, applicants respectfully submit that applicants' amended independent claim 29 and all claims dependent therefrom, including claims 30-36, 39, 44, 45, and 52-54, are allowable over Gilles. Therefore, applicants respectfully request that the rejections of claims 29-32 and 36 under 35 U.S.C. § 102(b) with respect to Gilles be withdrawn.

The Rejections Under 35 U.S.C. § 103(a)

Claims 33-35 and 39

Claims 33-35 and 39 have been rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Gilles. Applicants respectfully submit that each one of claims 33-35 and 39, which depends from applicants' amended independent claim 29, is allowable

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
88 of 363

over Gilles for at least some of the same reasons as applicants' amended independent claim 29 is allowable over Gilles. Therefore, applicants respectfully request that the rejections of claims 33-35 and 39 under 35 U.S.C. § 103(a) with respect to Gilles be withdrawn be withdrawn.

Claims 40 and 42

Claims 40 and 42 have been rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Gilles. These rejections are respectfully traversed.

Applicants' amended independent claim 40 defines an electronic device for detecting a user's cardiac signal, including an enclosure, a display screen exposed to the user through an opening in the enclosure, a heart sensor configured to detect the user's cardiac signal, and a processor coupled to the heart sensor. The heart sensor includes a first lead embedded in a first portion of the enclosure of the electronic device, wherein the first portion of the electronic device comprises an enclosure of the electronic device, wherein the first lead is configured to detect a first electrical signal of the user's cardiac signal via the user's contact with at least one of the first lead and the first portion of the enclosure of the electronic device. The heart sensor also includes a second lead embedded in the display screen of the electronic device, wherein the second lead is configured to detect a second electrical signal of the user's cardiac signal via the user's contact with at least one of the second lead and the display screen of the electronic device. The processor is configured to process the first and second electrical signals of the user's cardiac signal.

For example, as shown in applicants' FIG. 3, "electronic device 300 can include additional lead 326 embedded in or behind display 302," where "[l]ead 326 can be operative to detect a user's

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
89 of 363

heart activity as the user moves a finger across display 302," and, "[u]sing lead 326, the electronic device can detect an electrical signal from a different portion of the user's body (e.g., leads 322 and 324 detect signals through a first hand, and lead 326 detects signals through the second hand), which can provide the processor with additional information for determining characteristics of the user's cardiac activity" (applicants' specification, paragraph [0043]).

Gilles is directed towards heart monitoring apparatus. Gilles' FIG. 5 shows apparatus including an auxiliary device 9 with a male coupling 11 on one face for coupling to a case 3, and a female coupling 12 on another face for coupling to auxiliary electrode 7. Auxiliary device 9 is connected to several other auxiliary electrodes 13, 14, and 15 which adhere to the patient's bust in pre-determined positions via wires, as shown in Gilles' FIG. 8.

Nowhere does Gilles show or suggest an electronic device with a heart sensor that includes "a first lead embedded in a first portion of [an] enclosure of the electronic device," as well as "a second lead embedded in [a] display screen [exposed to the user through an opening in the enclosure] of the electronic device, wherein the second lead is configured to detect a second electrical signal of the user's cardiac signal via the user's contact with at least one of the second lead and the display screen of the electronic device," as required by applicants' amended independent claim 40. That is, nowhere does Gilles show or suggest any electrode embedded in any enclosure portion of case 3 / auxiliary device 9, let alone show or suggest a first electrode embedded in an enclosure of case 3 / auxiliary device 9 and a second electrode embedded in a display screen exposed to a user through an opening in such an enclosure of case 3 / auxiliary device 9. Instead, each one of auxiliary electrodes 13, 14, and 15 of Gilles is distinct and independent from

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
90 of 363

case 3 / auxiliary device 9 and is remotely coupled to case 3 / auxiliary device 9 via one or more wires of Gilles' FIG. 8. Assuming, *arguendo*, that Gilles' auxiliary electrode 7 as coupled to case 3 / auxiliary device 9 may be equated with a first lead embedded in an enclosure of an electronic device, which applicants do not accept, nowhere does Gilles show or suggest any other electrode that may be embedded in case 3 / auxiliary device 9, let alone embedded in Gilles' display 24 as enclosed within case 3. In fact, each one of all other electrodes 13, 14, and 15 of Gilles' FIG. 8 is disclosed as being positioned at different positions along the user's body distanced via wires from the position at which case 3 / auxiliary device 9 / auxiliary electrode 7 / display 24 is positioned.

For at least these reasons, applicants respectfully submit that applicants' amended independent claim 40 and all claims dependent therefrom, including claims 42 and 46-51, are allowable over Gilles. Therefore, applicants respectfully request that the rejection of claims 40 and 42 under 35 U.S.C. § 103(a) with respect to Gilles be withdrawn.

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
91 of 363

Conclusion

In view of the foregoing, applicants respectfully submit that claims 29-36, 39, 40, 42, and 44-54 are allowable. This application is therefore in condition for allowance. Reconsideration and prompt allowance of this application are respectfully requested.

Respectfully submitted,

Date: September 2, 2016

/Jeffrey C. Aldridge/

Jeffrey C. Aldridge
Registration No. 51,390
Attorney for Applicants
Van Court & Aldridge LLP
Customer No. 111349
154 Grand Street
New York, New York 10013
Tel.: (347) 470-6620

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
92 of 363

Doc Code: PET.OP
Document Description: Petition for Review by the Office of Petitions

PTO/SB/64 (12-13)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(a)

Page 1 of 2

Docket Number (Optional)
P7276USC1

First named inventor: Gloria Lin

Application No.: 14/136,658 Art Unit: 3762

Filed: December 20, 2013 Examiner: Alyssa Margo Alter Morschauser

Title: SEAMLESSLY EMBEDDED HEART RATE MONITOR

Attention: Office of Petitions
Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
FAX (571) 273-8300

NOTE: If information or assistance is needed in completing this form, please contact the Office of Petitions at (571) 272-3282.

The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the Office notice or action plus any extensions of time actually obtained.

APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION.

NOTE: A grantable petition requires the following items:

(1) Petition fee;
(2) Reply and/or issue fee;
(3) Terminal disclaimer with disclaimer fee – required for all utility and plant applications filed before June 8, 1995, and for all design applications; and
(4) Statement that the entire delay was unintentional.

1. **Petition fee**

☐ Small entity fee $ _____ (37 CFR 1.17(m)). Applicant asserts small entity status. See 37 CFR 1.27.

☑ Undiscounted fee $ 1,700 (37.CFR.1.17(m)).

2. **Reply and/or fee**

A The reply and/or fee to the above-noted Office notice or action in the form of

Request for Continued Examination; Reply to Final Office Action (identify the type of reply):

☐ has been filed previously on _____.

☑ is enclosed herewith.

B The issue fee and publication fee (if applicable) of $ _____

☐ has been paid previously on _____.

☐ is enclosed herewith.

This collection of information is required by 37 CFR 1.137(a). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11, 1.14 and 41.6. This collection is estimated to take 1 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Doc Code: PET.OP
Document Description: Petition for Review by the Office of Petitions

PTO/SB/64 (12-13)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(a)

3. **Terminal disclaimer with disclaimer fee**

☐ Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required.

☐ A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of $ _____) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).

4. **STATEMENT**: The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(a) was unintentional. [NOTE: The United States Patent and Trademark Office may require additional information if there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137(a) was unintentional (MPEP 711.03(c), subsections (III)(C) and (D)).]

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

/Jeffrey C. Aldridge/
Signature

September 4, 2016
Date

Jeffrey C. Aldridge
Typed or Printed Name

51,390
Registration Number, if applicable

154 Grand Street
Address

(347) 470-6620
Telephone Number

New York, New York 10013
Address

Enclosures:

☑ Fee Payment
☑ Reply
☐ Terminal Disclaimer Form
☐ Additional sheet(s) containing statements establishing unintentional delay
☑ Other: Request for Continued Examination

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]

I hereby certify that this correspondence is being:

☐ Deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

☑ Transmitted by EFS-Web or facsimile on the date shown below to the United States Patent and Trademark Office at (571) 273-8300.

September 4, 2016
Date

/Jeffrey C. Aldridge/
Signature

Jeffrey C. Aldridge
Typed or printed name of person signing certificate

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Patent Application Fee Transmittal

Application Number:	14136658
Filing Date:	20-Dec-2013
Title of Invention:	SEAMLESSLY EMBEDDED HEART RATE MONITOR
First Named Inventor/Applicant Name:	Gloria Lin
Filer:	Andrew Michael Van Court/Daniel Harris
Attorney Docket Number:	P7276USC1

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Claims in Excess of 20	1202	3	80	240
Miscellaneous-Filing:				
Petition:				
Pet. Revive Abandon App, Delay Pymt-Resp	1453	1	1700	1700
Patent-Appeals-and-Interference:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Extension - 3 months with $200 paid	1253	1	1200	1200
Miscellaneous:				
RCE- 1st Request	1801	1	1200	1200
		Total in USD ($)		**4340**

Electronic Acknowledgement Receipt

EFS ID:	26833279
Application Number:	14136658
International Application Number:	
Confirmation Number:	2657
Title of Invention:	SEAMLESSLY EMBEDDED HEART RATE MONITOR
First Named Inventor/Applicant Name:	Gloria Lin
Customer Number:	111349
Filer:	Andrew Michael Van Court/Daniel Harris
Filer Authorized By:	Andrew Michael Van Court
Attorney Docket Number:	P7276USC1
Receipt Date:	04-SEP-2016
Filing Date:	20-DEC-2013
Time Stamp:	21:16:53
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	$4340
RAM confirmation Number	090616INTEFSW21202500
Deposit Account	4115
Authorized User	Rachael Jung

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.16 (National application filing, search, and examination fees)

37 CFR 1.17 (Patent application and reexamination processing fees)

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
98 of 363

37 CFR 1.19 (Document supply fees)

37 CFR 1.20 (Post Issuance fees)

37 CFR 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		2016-09-04_P7276USC1-RCE-Resp-Final-docs.pdf	4295631 39e8a8909169a16975e0990ae92f2754098add56	yes	20

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Request for Continued Examination (RCE)	1	2
	Response After Final Action	3	3
	Claims	4	11
	Applicant Arguments/Remarks Made in an Amendment	12	20

Warnings:					
Information:					
2	Petition for review by the Office of Petitions	2016-09-04_P7276USC1_Petition-Revival.pdf	275390 ec57a86c0e4e7700d895b3912743551b70e6ad1f	no	3
Warnings:					
Information:					
3	Fee Worksheet (SB06)	fee-info.pdf	35848 95ceb6876d77035c798543f8d98906d827f3fee9	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	4606869		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Electronic Acknowledgement Receipt

EFS ID:	26833279
Application Number:	14136658
International Application Number:	
Confirmation Number:	2657
Title of Invention:	SEAMLESSLY EMBEDDED HEART RATE MONITOR
First Named Inventor/Applicant Name:	Gloria Lin
Customer Number:	111349
Filer:	Andrew Michael Van Court/Daniel Harris
Filer Authorized By:	Andrew Michael Van Court
Attorney Docket Number:	P7276USC1
Receipt Date:	04-SEP-2016
Filing Date:	20-DEC-2013
Time Stamp:	21:16:53
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	$4340
RAM confirmation Number	090616INTEFSW21202500
Deposit Account	506007
Authorized User	Rachael Jung

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.16 (National application filing, search, and examination fees)

37 CFR 1.17 (Patent application and reexamination processing fees)

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
101 of 363

37 CFR 1.19 (Document supply fees)

37 CFR 1.20 (Post Issuance fees)

37 CFR 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		2016-09-04_P7276USC1-RCE-Resp-Final-docs.pdf	4295631 39e8a8909169a16975e0990ae92f2754098add56	yes	20

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Request for Continued Examination (RCE)	1	2
	Response After Final Action	3	3
	Claims	4	11
	Applicant Arguments/Remarks Made in an Amendment	12	20

Warnings:					
Information:					
2	Petition for review by the Office of Petitions	2016-09-04_P7276USC1_Petition-Revival.pdf	275390 ec57a86c0e4e7700d895b3912743551b70e6ad1f	no	3
Warnings:					
Information:					
3	Fee Worksheet (SB06)	fee-info.pdf	35848 95ceb6876d77035c798543f8d98906d827f3fee9	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	4606869		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number	Filing Date	☐ To be Mailed
14/136,658	12/20/2013	

ENTITY: ☒ LARGE ☐ SMALL ☐ MICRO

APPLICATION AS FILED – PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X $ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X $ =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

APPLICATION AS AMENDED – PART II

AMENDMENT **09/04/2016**

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	* 27	Minus	** 24	= 3	X $80 =	240
Independent (37 CFR 1.16(h))	* 3	Minus	***3	= 0	X $420 =	0
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	**240**

AMENDMENT

	(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	RATE ($)	ADDITIONAL FEE ($)
Total (37 CFR 1.16(i))	*	Minus	**	=	X $ =	
Independent (37 CFR 1.16(h))	*	Minus	***	=	X $ =	
☐ Application Size Fee (37 CFR 1.16(s))						
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))						
					TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

SLIE
KIMBERLY WHITE

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/136,658	12/20/2013	Gloria Lin	P7276USC1	2657

111349 7590 08/10/2016

Van Court & Aldridge LLP
Apple Inc.
154 Grand St.
New York, NY 10013

EXAMINER
ALTER MORSCHAUSER, ALYSSA MARGO

ART UNIT	PAPER NUMBER
3762	

NOTIFICATION DATE	DELIVERY MODE
08/10/2016	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

docket@vcaiplaw.com
jaldridge@vcaiplaw.com
avancourt@vcaiplaw.com

Advisory Action Before the Filing of an Appeal Brief	**Application No.** 14/136,658	**Applicant(s)** LIN ET AL.	
	Examiner Alyssa M. Alter	**Art Unit** 3762	**AIA (First Inventor to File) Status** No

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 30 June 2016 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

NO NOTICE OF APPEAL FILED

1. ☒ The reply was filed after a final rejection. No Notice of Appeal has been filed. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114 if this is a utility or plant application. Note that RCEs are not permitted in design applications. The reply must be filed within one of the following time periods:
   a) ☐ The period for reply expires _____months from the mailing date of the final rejection.
   b) ☒ The period for reply expires on: (1) the mailing date of this Advisory Action; or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.
   c) ☐ A prior Advisory Action was mailed more than 3 months after the mailing date of the final rejection in response to a first after-final reply filed within 2 months of the mailing date of the final rejection. The current period for reply expires months from the mailing date of *the prior Advisory Action* or SIX MONTHS from the mailing date of the final rejection, whichever is earlier.
   Examiner Note: If box 1 is checked, check either box (a), (b) or (c). ONLY CHECK BOX (b) WHEN THIS ADVISORY ACTION IS THE FIRST RESPONSE TO APPLICANT'S FIRST AFTER-FINAL REPLY WHICH WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. ONLY CHECK BOX (c) IN THE LIMITED SITUATION SET FORTH UNDER BOX (c). See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) or (c) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. ☐ The Notice of Appeal was filed on _____. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AMENDMENTS

3. ☒ The proposed amendments filed after a final rejection, but prior to the date of filing a brief, will not be entered because
   a) ☐ They raise new issues that would require further consideration and/or search (see NOTE below);
   b) ☐ They raise the issue of new matter (see NOTE below);
   c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
   d) ☒ They present additional claims without canceling a corresponding number of finally rejected claims.
   NOTE: *See Continuation Sheet*. (See 37 CFR 1.116 and 41.33(a)).
4. ☐ The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
5. ☐ Applicant's reply has overcome the following rejection(s): _____.
6. ☐ Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
7. ☐ For purposes of appeal, the proposed amendment(s): (a) ☐ will not be entered, or (b) ☐ will be entered, and an explanation of how the new or amended claims would be rejected is provided below or appended.

AFFIDAVIT OR OTHER EVIDENCE

8. ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.
9. ☐ The affidavit or other evidence filed after final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).
10. ☐ The affidavit or other evidence filed after the date of filing the Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing of good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).
11. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

12. ☒ The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.
13. ☐ Note the attached Information *Disclosure Statement*(s). (PTO/SB/08) Paper No(s). _____
14. ☐ Other: _____.

STATUS OF CLAIMS

15. The status of the claim(s) is (or will be) as follows:
    Claim(s) allowed: .
    Claim(s) objected to: .
    Claim(s) rejected: 29-36,39,40 and 42.
    Claim(s) withdrawn from consideration: .

/Alyssa M Alter/
Primary Examiner

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257

Continuation of 3. NOTE: Claims 44-51 were added without cancelling a corresponding number of finally rejection of claims .

Continuation of 12. does NOT place the application in condition for allowance because: The propsed amendments will not be entered since they present additional claims (claims 44-51) without canceling a corresponding number of finally rejected claims. Additionally, the Applicant's arguments that Gilles fails to disclose a first and second lead is unpersusaive. The lead(s) of Gilles communicate Asensed signals and thus are "configured to detect" electrical signals. As such, for these reasons, as well as the ones previously made of record, the claims remain rejected.

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
107 of 363

PATENTS
P7276USC1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Gloria Lin et al.
Application No.	:	14/136,658 Confirmation No.: 2657
Filed	:	December 20, 2013
For	:	SEAMLESSLY EMBEDDED HEART RATE MONITOR
Art Unit	:	3762
Examiner	:	Alyssa Margo Alter Morschauser

New York, New York 10013
June 30, 2016

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

REPLY TO FINAL OFFICE ACTION

Sir:

This is in response to the Final Office Action mailed March 2, 2016 (hereinafter "the Office Action"). Applicants hereby respond as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper; and

Remarks begin on page 9 of this paper.

DO NOT ENTER: /A.M.A/

PATENTS
P7276USC1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Gloria Lin et al.
Application No.	:	14/136,658 Confirmation No.: 2657
Filed	:	December 20, 2013
For	:	SEAMLESSLY EMBEDDED HEART RATE MONITOR
Art Unit	:	3762
Examiner	:	Alyssa Margo Alter Morschauser

New York, New York 10013
June 30, 2016

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

REPLY TO FINAL OFFICE ACTION

Sir:

This is in response to the Final Office Action mailed March 2, 2016 (hereinafter "the Office Action"). Applicants hereby respond as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper; and

Remarks begin on page 9 of this paper.

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. - 23. (Cancelled)

24. (Withdrawn) An electronic device comprising:

a bezel, wherein an outer surface of at least a portion of the bezel comprises a first visual characteristic; and

a heart sensor coupled to the at least a portion of the bezel and operative to detect a user's cardiac signal, wherein an outer surface of the heart sensor comprises a second visual characteristic that matches the first visual characteristic.

25. (Withdrawn) The electronic device of claim 24, wherein each of the outer surface of the at least a portion of the bezel and the outer surface of the heart sensor comprises a portion of an outer surface of the electronic device.

26. (Withdrawn) The electronic device of claim 24, wherein:

the outer surface of the at least a portion of the bezel comprises a first finish; and

the outer surface of the heart sensor comprises a second finish that matches the first finish.

27. (Withdrawn) The electronic device of claim 24, wherein the outer surface of the heart sensor comprises a conductive coating that provides the second visual characteristic.

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
110 of 363

28. (Withdrawn) The electronic device of claim 24, wherein each of the first visual characteristic and the second visual characteristic comprises at least one of:

a particular color;

a particular tone; and

a particular reflectivity.

29. (Previously Presented) An electronic device for detecting a user's cardiac signal, comprising:

an enclosure;

a heart sensor configured to detect the user's cardiac signal, the heart sensor comprising:

a first lead embedded in a first portion of the enclosure, wherein an exterior surface of the enclosure comprises an exterior surface of the first portion, wherein the first lead is positioned underneath the exterior surface of the first portion, and wherein the first lead is configured to detect a first electrical signal of the user's cardiac signal via the user's contact with the exterior surface of the first portion of the enclosure; and

a second lead embedded in a second portion of the enclosure, wherein the second lead is configured to detect a second electrical signal of the user's cardiac signal via the user's contact with at least one of the second lead and the second portion of the enclosure; and

a processor coupled to the heart sensor and configured to receive and process the detected cardiac signal.

30. (Previously Presented) The electronic device of claim 29, wherein the first portion and the second portion are located on opposite sides of the electronic device.

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
111 of 363

31. (Previously Presented) The electronic device of claim 29, wherein the first portion is electrically isolated from the second portion.

32. (Previously Presented) The electronic device of claim 29, wherein:

the first portion is separated from the second portion by a third portion of the enclosure;

at least the third portion is constructed from a material having a first conductivity; and

the first conductivity is insufficient to transmit the first electrical signal from the first lead to the second lead via the third portion.

33. (Previously Presented) The electronic device of claim 32, wherein:

the material having the first conductivity comprises one of aluminum and steel; and

the second lead is constructed from a silver based compound.

34. (Previously Presented) The electronic device of claim 32, wherein:

the exterior surface of the enclosure further comprises an exterior surface of the second portion;

the second lead is configured to detect the second electrical signal of the user's cardiac signal via the user's contact with the exterior surface of the second portion;

the second lead is positioned from the exterior surface of the second portion by a thickness of the second portion;

at least the thickness of the second portion is

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
112 of 363

constructed from material having a second conductivity; and

the second conductivity is defined such that the second electrical signal is not able to be transmitted through material having the second conductivity over a distance larger than the thickness of the second portion.

35. (Previously Presented) The electronic device of claim 34, wherein the first lead and the second lead are positioned apart from one another at a distance larger than the thickness of the second portion by material having the second conductivity.

36. (Previously Presented) The electronic device of claim 29, wherein:

the enclosure further comprises at least one pocket underneath the exterior surface of the enclosure; and

at least one of the first lead and the second lead is placed within the at least one pocket.

37. (Cancelled)

38. (Cancelled)

39. (Previously Presented) The electronic device of claim 29, further comprising:

a display, wherein the enclosure supports the display, and wherein at least a portion of the exterior surface of the enclosure forms at least a portion of an exterior surface of the electronic device behind the display; and

a third lead embedded with the display, wherein the third lead is configured to detect a third electrical signal of the

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
113 of 363

user's cardiac signal via the user's contact with at least one of the third lead and the display.

40. (Previously Presented) An electronic device for detecting a user's cardiac signal, comprising:

a heart sensor configured to detect the user's cardiac signal, the heart sensor comprising:

a first lead embedded in a first portion of the electronic device, wherein the first lead is configured to detect a first electrical signal of the user's cardiac signal via the user's contact with at least one of the first lead and the first portion of the electronic device; and

a second lead embedded in a second portion of the electronic device, wherein the second lead is configured to detect a second electrical signal of the user's cardiac signal via the user's contact with at least one of the second lead and the second portion of the electronic device; and

a processor coupled to the heart sensor and configured to process the first and second electrical signals of the user's cardiac signal, wherein:

the first portion of the electronic device comprises an enclosure of the electronic device; and

the second portion of the electronic device comprises a display screen exposed to the user through an opening in the enclosure of the electronic device.

41. (Cancelled)

42. (Previously Presented) The electronic device of claim 40, wherein:

the first portion of the electronic device comprises a

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
114 of 363

bezel of the enclosure;

the electronic device further comprises a non-conductive component positioned between the bezel and the display screen for electrically isolating the first portion of the electronic device from the second portion of the electronic device.

43. (Cancelled)

44. (New) The electronic device of claim 29, wherein the second lead is configured to detect the second electrical signal of the user's cardiac signal via the user's contact with the second portion of the enclosure.

45. (New) The electronic device of claim 29, wherein the second lead is configured to detect the second electrical signal of the user's cardiac signal via the user's contact with the second lead.

46. (New) The electronic device of claim 40, wherein the first lead is configured to detect the first electrical signal of the user's cardiac signal via the user's contact with the first lead.

47. (New) The electronic device of claim 46, wherein the second lead is configured to detect the second electrical signal of the user's cardiac signal via the user's contact with the second lead.

48. (New) The electronic device of claim 46, wherein the second lead is configured to detect the second electrical signal of the user's cardiac signal via the user's contact with the second portion of the electronic device.

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
115 of 363

49. (New) The electronic device of claim 40, wherein the first lead is configured to detect the first electrical signal of the user's cardiac signal via the user's contact with the first portion of the electronic device.

50. (New) The electronic device of claim 49, wherein the second lead is configured to detect the second electrical signal of the user's cardiac signal via the user's contact with the second lead.

51. (New) The electronic device of claim 49, wherein the second lead is configured to detect the second electrical signal of the user's cardiac signal via the user's contact with the second portion of the electronic device.

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
116 of 363

REMARKS

Introduction

Claims 1-23, 37, 38, 41, and 43 have been cancelled without prejudice. Applicants hereby reserve the right to pursue the subject matter of one or more of cancelled claims in one or more continuation applications. Claims 24-28 have been withdrawn without prejudice. Claims 44-51 have been added. Claims 29-36, 39, 40, and 42 are also currently pending in the above-identified patent application. No new subject matter has been introduced and all amendments are fully supported by the application as originally filed.

Claims 29-32 and 36 have been rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Gilles et al. U.S. Patent No. 4,635,646 (hereinafter "Gilles").

Claims 33-35, 39, 40, and 42 have been rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Gilles.

A one-month extension of time in which to respond to the Final Office Action mailed March 2, 2016 is respectfully requested. The required fees are being paid by credit card, but the Director is authorized to charge any underpayment or to credit any overpayment to Deposit Account No. 50-6007.

Reconsideration and allowance of this application in light of the following remarks is hereby respectfully requested.

The Rejections Under 35 U.S.C. § 102(b)

Claims 29-32 and 36 have been rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Gilles. These rejections are respectfully traversed.

Applicants' independent claim 29 defines an electronic device for detecting a user's cardiac signal, including an enclosure, a heart sensor configured to detect the user's cardiac signal, and a processor coupled to the heart sensor. The heart sensor includes a

AliveCor Exhibit 1002
AliveCor, Inc. v. Apple Inc.
IPR2024-00169, U.S. Patent No. 10,076,257
117 of 363